Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    M. Alexander Otto, PA, MMS

    News

    Less Than 50% of Accelerated Approvals Show Clinical Benefit

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: April 9, 2024

    Researchers review 46 cancer drugs granted accelerated approvals between 2013 and 2017.

    • Read More

    News

    Abecma Approved for Earlier Lines in Relapsed/Refractory Multiple Myeloma

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: April 9, 2024

    The FDA greenlighted a costly CAR T-cell therapy for earlier lines in the treatment of adults with relapsed/refractory myeloma.

    • Read More

    News

    Eliminating H pylori Lowers CRC Incidence, Mortality Risk

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: April 9, 2024

    Investigators review CRC incidence and mortality in a nationwide cohort of veterans tested for H pylori.

    • Read More

    News

    Polygenic Risk Scores Improve Breast Cancer Screening

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: April 4, 2024

    Researchers examine how well polygenic risk scores predict a person's risk for any breast cancer as well as invasive, in situ, and bilateral at...

    • Read More

    News

    FDA OKs Danicopan Add-On for Extravascular Hemolysis in Adults With PNH

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: April 2, 2024

    Danicopan to support treatment of a rare blood disorder, paroxysmal nocturnal hemoglobinuria, is approved by the Food and Drug Administration.

    • Read More

    News

    Upfront Low-Dose Radiation Improves Advanced SCLC Outcomes

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: March 25, 2024

    Researchers compared their new findings with those of standard first-line treatment results from the 2019 CASPIAN trial.

    • Read More

    News

    FDA Approves Ponatinib for Upfront Ph+ ALL

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: March 20, 2024

    Accelerated approval of ponatinib in treating adults with a subtype of acute lymphoblastic leukemia has been granted by the FDA.

    • Read More

    News

    Zanubrutinib Label Expands to Include RR Follicular Lymphoma

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: March 8, 2024

    The FDA gives expedited approval to zanubrutinib for treating relapsed or refractory cases of the most common type of non-Hodgkin lymphoma.

    • Read More

    News

    Nivolumab Wins First-Line Indication in Metastatic Urothelial Carcinoma

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: March 8, 2024

    Median overall survival was 21.7 months with nivolumab add-on vs 18.9 months with cisplatin/gemcitabine alone.

    • Read More

    News

    Pfizer Antibody-Drug Conjugate Picks Up Pediatric ALL Indication

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: March 7, 2024

    The FDA has given pediatric approval for inotuzumab ozogamicin to treat some types of relapsed or refractory acute lymphoblastic leukemia.

    • Read More

    News

    Doxorubicin Increases Breast Cancer Risk in Women With Hodgkin Lymphoma

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: February 27, 2024

    Investigators review breast cancer incidence in nearly 2,000 women treated for Hodgkin lymphoma.

    • Read More

    News

    Transcatheter Arterial Chemoembolization for Rectal Tumors?

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: February 20, 2024

    Overall, 20.7% of patients undergoing transcatheter arterial chemoembolization had a pathological complete response.

    • Read More

    News

    Hyperbaric Oxygen: Effective Against Cancer Radiation Harm?

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: February 16, 2024

    New study on hyperbaric oxygen therapy does not clarify benefit for patients following radiation.

    • Read More

    News

    Regrowth Predicts Metastasis in Rectal Cancer Watch and Wait

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: February 8, 2024

    Investigators compared outcomes for ‘watch-and-wait’ patients with those who had total mesorectal excisions after neoadjuvant therapy.

    • Read More

    News

    The Case for Biomarker Testing in Gastroesophageal Cancer

    Author:
    M. Alexander Otto, PA, MMS
    Publish date: January 24, 2024

    Expert provides top three picks for biomarker testing for treatment selection.

    • Read More

    Pages

    • « first
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery